Author:
Pradhan Richeek,Patorno Elisabetta,Tesfaye Helen,Schneeweiss Sebastian,Yin Hui,Franklin Jessica,Pawar Ajinkya,Santella Christina,Yu Oriana H Y,Renoux Christel,Azoulay Laurent
Abstract
Abstract
Case reports and a pharmacovigilance analysis have linked glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with anaphylactic reactions, but real-world evidence for this possible association is lacking. Using databases from the United Kingdom (Clinical Practice Research Datalink) and the United States (Medicare, Optum (Optum, Inc., Eden Prairie, Minnesota), and IBM MarketScan (IBM, Armonk, New York)), we employed a new-user, active comparator study design wherein initiators of GLP-1 RAs were compared with 2 different active comparator groups (initiators of dipeptidyl peptidase 4 (DPP-4) inhibitors and initiators of sodium-glucose cotransporter 2 (SGLT-2) inhibitors) between 2007 and 2019. Propensity score fine stratification weighted Cox proportional hazards models were fitted to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for an anaphylactic reaction. Database-specific HRs were pooled using random-effects models. Compared with the use of DPP-4 inhibitors (n = 1,641,520), use of GLP-1 RAs (n = 324,098) generated a modest increase in the HR for anaphylactic reaction, with a wide 95% CI (36.9 per 100,000 person-years vs. 32.1 per 100,000 person-years, respectively; HR = 1.15, 95% CI: 0.94, 1.42). Compared with SGLT-2 inhibitors (n = 366,067), GLP-1 RAs (n = 259,929) were associated with a 38% increased risk of anaphylactic reaction (40.7 per 100,000 person-years vs. 29.4 per 100,000 person-years, respectively; HR = 1.38, 95% CI: 1.02, 1.87). In this large, multisite population-based cohort study, GLP-1 RAs were associated with a modestly increased risk of anaphylactic reaction when compared with DPP-4 inhibitors and SGLT-2 inhibitors.
Funder
Canadian Institutes of Health Research
Brigham and Women’s Hospital
Harvard Medical School
Fonds de Recherche du Québec-Santé
National Institute on Aging
US National Institutes of Health
McGill University
Boehringer Ingelheim
Union Chimique Belge
Publisher
Oxford University Press (OUP)
Reference34 articles.
1. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis;Bethel;Lancet Diabetes Endocrinol.,2018
2. 8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2018;American Diabetes Association;Diabetes Care,2018
3. Adverse effects of GLP-1 receptor agonists;Filippatos;Rev Diabetic Stud.,2014
4. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes;Tran;Am Health Drug Benefits.,2017
5. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities;Lund;Eur J Intern Med.,2014
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献